Daniela Salvemini, Ph.D., Professor of Pharmacology and Physiology, received a grant from The Mayday Fund to determine if either of two key molecules, S1PR1 and A3AR, are biomarkers of pain associated with four conditions: chemotherapy-induced neuropathy, endometriosis, interstital cystitis, and vulvodynia.

Chronic pain is often managed using opioids, which can be highly addictive and have severe side effects. Researchers previously found that modulating S1PR1 and A2AR blocked or reversed pain, making them prime targets to develop new treatments for this type of pain.

Researchers will now determine whether either of the molecules can be used as a biomarker to measure whether or not someone is suffering from pain via this pathway, and to determine if medication is treating the pain effectively. She will work with several SLU clinicians for this study in order to follow patients experiencing pain from the four conditions.

For more information, read the full article in Newslink.